NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

06 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

15 Feb 2024 16:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

01 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL

16 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

08 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

11 Dec 2023 12:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting

04 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

07 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

02 Nov 2023 09:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

01 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

12 Oct 2023 16:01:00 By Nasdaq GlobeNewswire

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics

07 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

31 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

13 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

14 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

09 May 2023 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

17 Apr 2023 14:30:00 By Nasdaq GlobeNewswire